These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation. Tada T; Kadota K; Hosogi S; Miyake K; Ohya M; Amano H; Izawa Y; Kanazawa T; Kubo S; Ichinohe T; Hyoudou Y; Hayakawa Y; Sabbah MM; Otsuru S; Hasegawa D; Habara S; Tanaka H; Fuku Y; Katoh H; Goto T; Mitsudo K Eur Heart J Cardiovasc Imaging; 2015 Oct; 16(10):1101-11. PubMed ID: 25762559 [TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of randomized trials comparing the effectiveness of different strategies for the treatment of drug-eluting stent restenosis. Piccolo R; Galasso G; Piscione F; Esposito G; Trimarco B; Dangas GD; Mehran R Am J Cardiol; 2014 Nov; 114(9):1339-46. PubMed ID: 25242363 [TBL] [Abstract][Full Text] [Related]
5. A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study. Naganuma T; Latib A; Sgueglia GA; Menozzi A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Panoulas VF; Buffoli F; Tamburino C; Varbella F; Colombo A Int J Cardiol; 2015 Apr; 184():17-21. PubMed ID: 25705005 [TBL] [Abstract][Full Text] [Related]
7. Local delivery of paclitaxel in the treatment of peripheral arterial disease. Ng VG; Mena C; Pietras C; Lansky AJ Eur J Clin Invest; 2015 Mar; 45(3):333-45. PubMed ID: 25615282 [TBL] [Abstract][Full Text] [Related]
9. Evidence for the use of drug eluting stents in below-the-knee lesions. Trombert D; Caradu C; Brizzi V; Bérard X; Midy D; Ducasse E J Cardiovasc Surg (Torino); 2015 Feb; 56(1):67-71. PubMed ID: 25428562 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Granada JF; Stenoien M; Buszman PP; Tellez A; Langanki D; Kaluza GL; Leon MB; Gray W; Jaff MR; Schwartz RS Open Heart; 2014; 1(1):e000117. PubMed ID: 25332821 [TBL] [Abstract][Full Text] [Related]
11. Drug-eluting stents and acute myocardial infarction: A lethal combination or friends? Otsuki S; Sabaté M World J Cardiol; 2014 Sep; 6(9):929-38. PubMed ID: 25276295 [TBL] [Abstract][Full Text] [Related]
12. Cilostazol regulates the expressions of endothelin-1 and endothelial nitric oxide synthase via activation of the p38 MAPK signaling pathway in HUVECs. Xue Y; Li X; Wang Z; Lv Q Biomed Rep; 2022 Sep; 17(3):77. PubMed ID: 35950100 [TBL] [Abstract][Full Text] [Related]
13. Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach. Hassan S; Ali MN; Ghafoor B J Cardiothorac Surg; 2022 Apr; 17(1):65. PubMed ID: 35379273 [TBL] [Abstract][Full Text] [Related]
14. Long Non-Coding RNAs Might Regulate Phenotypic Switch of Vascular Smooth Muscle Cells Acting as ceRNA: Implications for In-Stent Restenosis. Arencibia A; Lanas F; Salazar LA Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328496 [TBL] [Abstract][Full Text] [Related]
16. Vascular Wall Reactions to Coronary Stents-Clinical Implications for Stent Failure. Gori T Life (Basel); 2021 Jan; 11(1):. PubMed ID: 33477361 [TBL] [Abstract][Full Text] [Related]
17. Association study of matrix metalloproteinase 3 5A/6A polymorphism with in-stent restenosis after percutaneous coronary interventions in a Han Chinese population. Du JB; Zhang W; Li N; Jiang H; Liu Y; Gao J; Chen ST; Cong HL; Wei YL J Int Med Res; 2020 Jan; 48(1):300060519827145. PubMed ID: 30732526 [TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. Xue Y; Feng ZW; Li XY; Hu ZH; Xu Q; Wang Z; Cheng JH; Shi HT; Wang QB; Wu HY; Xie XQ; Lv QZ Acta Pharmacol Sin; 2018 Feb; 39(2):205-212. PubMed ID: 28933424 [TBL] [Abstract][Full Text] [Related]
19. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA; Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678 [TBL] [Abstract][Full Text] [Related]
20. Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis. Zhao SJ; Zhong ZS; Qi GX; Shi LY; Chen L; Tian W PLoS One; 2016; 11(5):e0155273. PubMed ID: 27163676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]